These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30810925)

  • 1. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion.
    Vimpolsek M; Gottar-Guillier M; Rossy E
    Drugs R D; 2019 Jun; 19(2):127-140. PubMed ID: 30810925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev
    Weiser S; Burns C; Zartler ER
    J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera
    Weiser S; Burns C; Zartler ER
    J Oncol Pharm Pract; 2023 Apr; 29(3):590-600. PubMed ID: 35072574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties.
    Yun J; Kim J; Chung J; Hwang SJ; Park SJ
    Adv Ther; 2019 Jul; 36(7):1700-1714. PubMed ID: 31102205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis.
    Palaparthy R; Rehman MI; von Richter O; Yin D
    Expert Opin Biol Ther; 2019 Oct; 19(10):1065-1074. PubMed ID: 31284794
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.
    Alten R; Batko B; Hala T; Kameda H; Radominski SC; Tseluyko V; Babic G; Cronenberger C; Hackley S; Rehman M; von Richter O; Zhang M; Cohen S
    RMD Open; 2019; 5(1):e000876. PubMed ID: 30997153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
    Lamanna WC; Heller K; Schneider D; Guerrasio R; Hampl V; Fritsch C; Schiestl M
    J Oncol Pharm Pract; 2019 Mar; 25(2):269-278. PubMed ID: 28950806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima
    Kim SJ; Kim KW; Shin YK; Kwon JW; Kang HY; Park YA; Shin JY; Kim SY; Han WY
    BioDrugs; 2019 Apr; 33(2):221-228. PubMed ID: 30747341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
    Cohen SB; Radominski SC; Kameda H; Kivitz AJ; Tee M; Cronenberger C; Zhang M; Hackley S; Rehman MI; von Richter O; Alten R
    BioDrugs; 2020 Apr; 34(2):197-207. PubMed ID: 31939063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
    Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
    BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.
    Kameda H; Uechi E; Atsumi T; Abud-Mendoza C; Kamei K; Matsumoto T; Ponce de Leon D; Rehman MI; Zhang M; Radominski SC
    Int J Rheum Dis; 2020 Jul; 23(7):876-881. PubMed ID: 32476277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
    Tak M; Jeong H; Yun J; Kim J; Kim S; Lee Y; Park SJ
    Drugs R D; 2023 Dec; 23(4):363-375. PubMed ID: 37606749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion.
    Kim SJ; Lee JW; Kang HY; Kim SY; Shin YK; Kim KW; Oh JS; Lim KJ; Kim JY
    BioDrugs; 2018 Dec; 32(6):619-625. PubMed ID: 30386977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged In-use Stability of Diluted Atezolizumab in Commercial Intravenous Bags.
    Hui A; Yin J; Liu W; Zheng K
    Int J Pharm Compd; 2021; 25(3):246-257. PubMed ID: 34125716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.
    McClellan JE; Conlon HD; Bolt MW; Kalfayan V; Palaparthy R; Rehman MI; Kirchhoff CF
    Therap Adv Gastroenterol; 2019; 12():1756284819852535. PubMed ID: 31223341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of infliximab solutions in different temperature and dilution conditions.
    Tokhadze N; Chennell P; Le Basle Y; Sautou V
    J Pharm Biomed Anal; 2018 Feb; 150():386-395. PubMed ID: 29287266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
    Park D; Kim J; Yun J; Park SJ
    Adv Ther; 2020 Oct; 37(10):4308-4324. PubMed ID: 32816233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
    Palaparthy R; Udata C; Hua SY; Yin D; Cai CH; Salts S; Rehman MI; McClellan J; Meng X
    Expert Rev Clin Immunol; 2018 Apr; 14(4):329-336. PubMed ID: 29504427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags.
    Nalenz H; Köpf E; Dietel E
    Int J Pharm Compd; 2018; 22(5):417-423. PubMed ID: 30384340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
    Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.